Imiquimod

This classification denotes a biological response modifier with the molecular formula C14H16N4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P1QW714R7M, chemically known as 4-amino-1-isobutyl-1h-imidazo(4,5-c)quinoline but generally known as imiquimod, which bears US NIH Compound Identifier 57469. European Medicines Agency schedules Imiquimod in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12453MIG. The term IMIQUIMOD is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 6, No, 3 1992, List 32). World Health Organization schedules imiquimod in its Anatomical Therapeutic Chemical (ATC) Classification. IMIQUIMOD is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule imiquimod under HS 29339990 and SITC 51577. As of Q4 2014, IMIQUIMOD remains the US FDA Preferred Term for this commodity. Imiquimod bears US NLM identifiers UMLS ID C0165032 and NCI Concept Code C1431. SMILES: N1(CC(C)C)C2C3C(NC(N)C2NC1)CCCC3.